21 47 1


MacroGenics has several positions for full-time employment currently open .

Learn more


MacroGenics is pursuing alliances to participate in development of its proprietary product candidates and technology platforms.

Learn more

In the News...

See what others are writing or saying about MacroGenics. Learn more

Press Releases

October 10, 2013
MacroGenics Announces Pricing of Initial Public Offering

September 19, 2013
MacroGenics' Board of Directors Elects Paulo F. Costa as Chairman

August 20, 2013
MacroGenics to Receive $10 Million Milestone Payment from Servier for Dosing the First Patient in a Phase 1 Dose Expansion Trial of MGA271

August 12, 2013
MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development

June 03, 2013
MacroGenics Presents Phase 1 Data at ASCO Showing Signs of Clinical Benefit for Margetuximab in HER2 Expressing Tumors; Phase 2 Clinical Trial Underway to Evaluate Activity in Patients with Advanced Breast Cancer

May 21, 2013
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer

January 07, 2013
MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART™ Products

September 20, 2012
MacroGenics and Servier Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DART™ Products

September 05, 2012
ImaginAb and MacroGenics Collaborate to Develop In Vivo Imaging Agents for Autoimmune Diseases, Cancer Imaging partnership to focus on key immunology targets to diagnose multiple diseases

December 20, 2011
MacroGenics Receives Milestone Payment as Part of its Global DART Alliance with Boehringer Ingelheim

Press Release Archive: 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | View All